CN1424110A - Vaccine adjuvant against hepatitis B - Google Patents
Vaccine adjuvant against hepatitis B Download PDFInfo
- Publication number
- CN1424110A CN1424110A CN 02159913 CN02159913A CN1424110A CN 1424110 A CN1424110 A CN 1424110A CN 02159913 CN02159913 CN 02159913 CN 02159913 A CN02159913 A CN 02159913A CN 1424110 A CN1424110 A CN 1424110A
- Authority
- CN
- China
- Prior art keywords
- hbv
- vaccine
- adjuvant
- csf
- therapeutic vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An adjuvant for the curative vaccine of hepatitis B virus is prepared from interleukin 2(IL-2), human granulocyte-macrophage colony stimulating factor (GM-CSF), and tetanus toxin derivative polypeptide (TT).
Description
The present invention relates to a kind of new vaccine adjuvant, be specifically related to anti-hepatitis B virus (HBV) therapeutic vaccine adjuvant.
Hepatitis B is by the high disease of the infectious sickness rate of HBV.Antiviral therapy is the main means of treatment chronic HBV infection.
So far develop many nucleoside analog antiviral agents the nineties in 20th century, wherein draw the miaow furan sting (Lamivudine) in 1998 by drugs approved by FDA, be used for the treatment of chronic viral hepatitis B.
In addition, the anti-HBV therapy of a kind of new specificity (anti-HBV therapeutic vaccine) is also developed, and wherein S and S fragment albumen and t cell epitope polypeptide therapeutic vaccine also come out before the HBV, and have been used for clinical treatment chronic HBV infection patient.Calendar year 2001 Merck institute research worker Hilleman on the Vaccine magazine brief overview treat the main Therapeutic Method of chronic HBV infection now in the world.Narrate the main antiviral therapy for the treatment of chronic HBV infection at present in the world in the article and comprised antiviral chemotherapy, interferons antiviral agents, biology therapy, specificity immunology therapy etc.Wherein the antiviral chemotherapy is used the nucleoside analog antiviral agents.The interferons antiviral agents has IFN-α 1,2a and 2b.Biology, therapy was to influence transcription behind the hbv replication, and this therapy is used materials such as cytokine (IFN-γ, TNF-α, IL-2 and IL-12), thymosin (Thymosin α 1), antisense nucleotide and antisensenucleic acids.The specificity immunology therapy is used anti-HBV specific immune globulin, anti-HBV therapeutic vaccine.Existing anti-HBV therapeutic vaccine mainly contains three kinds at present: preceding S and S fragment protein for treatment vaccine, t cell epitope fat polypeptide therapeutic vaccine and DNA plasmid vaccine.The existing clinical practice report of preceding two kinds of anti-HBV therapeutic vaccines, the DNA plasmid vaccine then still is in the external and zooperal stage owing to there is still unsolved safety problem.
According to the HBV amynologic mechanism of present discovery, chronic HBV infection patient's the effect that lapses to antiviral therapy has substantial connection.The only a few case is eliminated with the interior HBV of blood circulation in the liver in the antiviral therapy process, shows as HBsAg, HBeAg and HBV DNA clinically and disappears, even finally produce anti-HBs, obtains the radical treatment effect; Most of case then just during medication hbv replication be suppressed, show as HBeAg and HBV DNA clinically and in circulation blood, reach the level that detection does not go out.Yet recurrence in a period of time after the drug withdrawal turns back to the preceding situation of treatment.This present situation of antiviral therapy curative effect shows that the radical treatment problem of chronic HBV infection also solves far away.
In three kinds of above-mentioned existing anti-HBV therapeutic vaccines, first kind of anti-HBV therapeutic vaccine is made of first HBV specific antigen two kinds of preparations.General in the world HBV S fragment or Pre S and S fragment albumen are the HBV specific antigen; It two is immunological adjuvants.Two kinds of compositions all can influence the clinical efficacy of anti-HBV therapeutic vaccine.The quality of immunological adjuvant particularly, the quality of antagonism HBV therapeutic vaccine clinical efficacy plays a decisive role.
The major issue that chronic HBV infection patient immune system exists is an immunologic tolerance.Because immunologic tolerance makes patient's anti-HBV immunoreation lymphocyte not produce immunne response to HBV and antigen thereof, therefore make HBV be the persistent infection state in vivo.Modern immunologic research prompting, the unique channel that solves this state is to treat by using anti-HBV therapeutic vaccine, breaks immunologic tolerance.So, break chronic HBV infection patient's immunologic tolerance with anti-HBV therapeutic vaccine, rebuild its normal anti-HBV immunne response, be not only current a kind of new treatment approach, and be current up-to-date treatment thinking.
In above-mentioned three kinds of anti-HBV therapeutic vaccines, being considered to safe and effective in cure person now is anti-HBVPre S and S fragment protein for treatment vaccine.In this field, international competition is very fierce.Focusing in the development to this therapeutic vaccine adjuvant of competition.We can say that who works out best adjuvant, who just accounts for the superiors in international competition.
Aspect the research of adjuvant, most people liopopolysaccharides material commonly used or old tuberculin.Because we find in research for many years, why the chronic HBV infection patient is immune tolerance state to HBV, and very one of important reasons is patient's the last immune secondary signal (be called B7.1 and B7.2 or claim CD80 and CD86 polypeptide) that lacks of antigen processing cell (APCs).Just because this immune signal lacks, make two kinds of cells that start anti-HBV immunne response, promptly HBV antigenic specificity cytotoxic T cell (abbreviation specific CTL) (is called for short CD4 with helper T cell
+Cell or HTL) can not activate, and then intravital HBV can not be eliminated.
In view of the foregoing, the emphasis of inventor research is to develop peptide material with the immune secondary signal function adjuvant as anti-HBV therapeutic vaccine.After research for many years, we have had very big discovery, be that gene recombinaton interleukin II (IL-2), gene recombinaton GM-CSF and tetanus element (TT) polypeptide of deriving is combined by special ratios, add the Pre S and the S fragment protein vaccine of doses, can show two effects: 1. substitute the immune secondary signal that patient APCs lacks; 2. rebuild the anti-HBV immunne response that the patient loses.Up to the present the new approaches of the anti-HBV therapeutic vaccine adjuvant of this development, and the new adjuvant of developing on this new approaches basis, remain unique in the world.
The purpose of this invention is to provide new adjuvant, the adjuvant that is applicable to anti-HBV therapeutic vaccine particularly is provided.
One embodiment of the invention provide a kind of new vaccine adjuvant, and wherein said adjuvant is made up of interleukin II (IL-2), human granulocyte-macrophage colony stimulating factor (GM-CSF), TT (TT).IL-2 and GM-CSF can be native proteins, also can be recombiant proteins.IL-2, GM-CSF and TT all have commercially available, and IL-2 can obtain with injection recombinant human interleukin--2's ProductName from Fourth Ring, Beijing bioengineering product factory; GM-CSF can obtain with the trade name of Leucomax from Schering-Plough (Brinny) Co.; TT can obtain with the trade name of tetanus toxoid from Lanzhou Institute of Biological Products.In addition, the production method of IL-2, GM-CSF and TT also is known in the art, for example referring to Wong GG, witek JS, Temple PA, et al, Molecular cloning ofhuman and givvon GM-CSF cDNA ' s and purification of the natural and recombinanthuman proteins.Cancer Cells 1985; 3:235-242.
Another embodiment of the present invention provides the new adjuvant of being made up of interleukin II (IL-2), human granulocyte-macrophage colony stimulating factor (GM-CSF), TT (TT), the ratio of wherein said IL-2, GM-CSF and TT (weight ratio) is 50-600: 10-200: 6-20, and the part by weight of preferred IL-2, GM-CSF and TT is 56: 16: 6.Described three kinds of components contents can not be as the criterion by toxigenicity with the adjuvant of gained.
Adjuvant of the present invention can be used for vaccine, especially for anti-HBV therapeutic vaccine.
Get IL-2, GM-CSF and TT according to the above ratio and mix, promptly can be made into adjuvant of the present invention.According to method well known in the art, make water preparation or lyophilized formulations after said components can being made up in proportion.
Accompanying drawing Fig. 1 shows the effect of the anti-HBV therapeutic vaccine that uses adjuvant of the present invention.
Embodiment 1
Get 56 parts of recombinant il-2s (obtaining), 16 parts of GM-CSF (obtaining) and 6 parts of TT (obtaining) aqueous solution from Lanzhou Institute of Biological Products from Schering-Plough (Brinny) Co. from Fourth Ring, Beijing bioengineering product factory, mix, make lyophilized formulations according to " Chinese biological goods rules " (version in 2000, Chinese biological standard of articles committee compiles) disclosed method.
Embodiment 2
After above-mentioned adjuvant and doses HBV S fragment protein vaccine (the gene recombinaton Hepatitis B virus vaccine that obtains from Beijing Tiantan Bio-pharmaceuticals limited company) mix, immunity HBV transgenic mouse (1.3.32 Mus), when immunity finishes, Mus is put to death, get Hepar Mus and make leachate, extract total DNA in the liver by leachate, analyze HBV RC DNA and SS DNA in the liver, analyze gamma interferon (IFN-γ) and tumor necrosis factor-alpha (TNF-α) RNA with Northen blot method simultaneously with Southern blot method.In the experimentation, establish one group of matched group.Matched group 1.3.32 Mus is used the normal saline immunity.Experimental result such as Fig. 1.By figure one as seen, after the treatment group was treated with anti-HBV therapeutic vaccine, HBV RC DNA and SS DNA district band disappeared.High concentration IFN-γ and TNF-α RNA district band appears simultaneously.This description of test, anti-HBV therapeutic vaccine has anti-HBV effect to the HBV transgenic mouse, and it can remove the HBV DNA in the HBV transgenic Hepar Mus.After it was removed mechanism and injects anti-HBV therapeutic vaccine, generation high concentration IFN-γ and TNF-α were relevant in the liver.
Embodiment 3
Anti-HBV therapeutic vaccine 10 μ g immunity HBV transgenic mouse and normal control Mus (B6D2F with the foregoing description 2
1), the immunity back was surveyed the HBV specific cytotoxic t cell responses (abbreviation ctl response) of two kinds of Mus on the 11st day.Survey the preceding ctl response of two kinds of Mus immunity of the same race simultaneously.The result proves, B6D2F
1The preceding 90% pair of HBV S fragment albumen of Mus immunity has ctl response; After the immunity of anti-HBV therapeutic vaccine, its ctl response occurrence rate rises to 100%.And the HBV transgenic mouse before the immunity of anti-HBV therapeutic vaccine, has only 30% ctl response to occur, rises to 93% after the immunity.The overwhelming majority (70%) HBV transgenic mouse has immunologic tolerance (no ctl response) before this description of test, the immunity of anti-HBV therapeutic vaccine.After the immunity of anti-HBV therapeutic vaccine, immunologic tolerance is broken, and 93% ctl response occurs.Therefore the anti-HBV therapeutic vaccine of this description of test has the effect of the immunologic tolerance of breaking the HBV transgenic mouse.
Embodiment 4
Give with HBV S fragment albumen Hepatitis B virus vaccine (gene recombinaton) and to inject the normal person that Hepatitis B virus vaccine produces anti--HBs and do intradermal test, can measure 95% normal person occur the delayed intradermoreaction positive (be that erythema appears in the injection site, diameter＞0.5cm).Get erythema part skin and cut into slices, check the skin infiltration cell, prove that soaking into cell is CD8
+(CTL) cell and CD4
+(HTL) cell is main.Illustrate that the intradermoreaction that this intradermal test is drawn belongs to the delayed intradermoreaction, represent CTL and HTL cell the proteic cell immune response of HBV S fragment.Similar to external ctl response.95% has this intradermoreaction positive of anti--HBs normal person, and the internal reaction positive illustrates the normal person who produced anti--HBs through hepatitis b vaccine immune, and the overwhelming majority (95%) does not have immunologic tolerance.But check the Chronic HBV carrier with same intradermoreaction, then have only 5% to be positive, 95% is negative.Illustrate that the overwhelming majority (95%) Chronic HBV carrier has immunologic tolerance.With anti-HBV therapeutic vaccine treatment, 1 time every month, inject altogether 12 times, then 90% patient's intradermal test changes the positive into by feminine gender.Prove that anti-HBV therapeutic vaccine has the effect of breaking its immunologic tolerance to Chronic HBV carrier patient.
Claims (5)
1, a kind of new vaccine adjuvant is characterized in that described adjuvant is made up of interleukin II (IL-2), human granulocyte-macrophage colony stimulating factor (GM-CSF), TT (TT).
2, according to the vaccine adjuvant of claim 1, the part by weight of wherein said IL-2, GM-CSF and TT is 50-600: 10-200: 6-20.
3, according to the vaccine adjuvant of claim 1, the part by weight of wherein said IL-2, GM-CSF and TT is 56: 16: 6.
4, according to arbitrary vaccine adjuvant of claim 1-3, wherein said IL-2 and GM-CSF can be recombinant production.
5, the application of arbitrary vaccine adjuvant of claim 1-4 in anti-hepatitis B virus (HBV) therapeutic vaccine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159913 CN1424110A (en) | 2002-12-30 | 2002-12-30 | Vaccine adjuvant against hepatitis B |
| CN 03104697 CN1270772C (en) | 2002-12-30 | 2003-02-21 | Anti-hepatitis-B-virus therapeutic vaccine and its adjuvant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159913 CN1424110A (en) | 2002-12-30 | 2002-12-30 | Vaccine adjuvant against hepatitis B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1424110A true CN1424110A (en) | 2003-06-18 |
Family
ID=4753356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02159913 Pending CN1424110A (en) | 2002-12-30 | 2002-12-30 | Vaccine adjuvant against hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1424110A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305527C (en) * | 2003-11-21 | 2007-03-21 | 薛平 | Vaccine for treating hepatitis B, and its prepn. method |
| CN107007831A (en) * | 2017-06-16 | 2017-08-04 | 南京佰泰克生物技术有限公司 | The immunologic adjuvant of hepatitis B DNA vaccine |
-
2002
- 2002-12-30 CN CN 02159913 patent/CN1424110A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305527C (en) * | 2003-11-21 | 2007-03-21 | 薛平 | Vaccine for treating hepatitis B, and its prepn. method |
| CN107007831A (en) * | 2017-06-16 | 2017-08-04 | 南京佰泰克生物技术有限公司 | The immunologic adjuvant of hepatitis B DNA vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tighe et al. | Gene vaccination: plasmid DNA is more than just a blueprint | |
| US5151023A (en) | Hepatitis a,b-combined adjuvanted vaccine | |
| EP0671948B1 (en) | Vaccine composition containing adjuvants | |
| Qing et al. | Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice | |
| KR20220114031A (en) | Immune stimulating composition and use thereof | |
| US20220193228A1 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus | |
| AU2018233208B2 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
| Audibert et al. | Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens | |
| CN107693788B (en) | Pharmaceutical composition for preventing or treating hepatitis B and application thereof | |
| CN1270772C (en) | Anti-hepatitis-B-virus therapeutic vaccine and its adjuvant | |
| CN1424110A (en) | Vaccine adjuvant against hepatitis B | |
| WO2018166298A1 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
| AU9161591A (en) | Use of il-4 to enhance immune response to immunogens in vaccines | |
| EP1250933A1 (en) | Vaccines including as an adjuvant high dose type I IFN | |
| CN101095951B (en) | Therapeutic HBV DNA vaccines, method for preparing the same and application thereof | |
| US20120308615A1 (en) | Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization | |
| CN1315535C (en) | Adjuvant for improving hepatitis B vaccine immune effect and preparing method thereof | |
| CN101618211A (en) | Hepatitis B polypeptide vaccine and application thereof | |
| WO2019001173A1 (en) | Application of scd100 protein in preparing drug for treating chronic hbv infection | |
| El Battioui et al. | Strategies for the development of hepatitis B virus vaccines | |
| CA2840335C (en) | Recombinant mistletoe lectin and use thereof as an adjuvant | |
| Matsushita et al. | In vitro interferon producing activity of peripheral mononuclear cells in patients with chronic liver disease | |
| EA040981B1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES SURFACE AND NUCLEOCAPSID ANTIGENS OF HEPATITIS B VIRUS | |
| CN1435259A (en) | Preparation and use of chronic hepatitis B therapeutic DNA vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |